PUBLISHER: Meticulous Research | PRODUCT CODE: 2132854
PUBLISHER: Meticulous Research | PRODUCT CODE: 2132854
Minimal Residual Disease Testing Market Size, Share, Forecast, And Trends Analysis by Offering, Type, Technology, Application, End User, and Geography - Global Forecast to 2036
The global Minimal Residual Disease (MRD) Testing Market is estimated to be valued at USD 2.7 billion in 2026 and is projected to reach USD 13.6 billion by 2036, expanding at a CAGR of 17.5% during the forecast period. The report provides a comprehensive evaluation of the rapidly evolving MRD testing market by examining market trends, technological advancements, clinical applications, regulatory developments, and future growth opportunities across the oncology and precision medicine landscape.
Minimal residual disease testing enables the detection of small numbers of cancer cells that remain in a patient following treatment or clinical remission. Because these cells occur at very low concentrations, MRD detection requires highly sensitive technologies, including flow cytometry, polymerase chain reaction, and next-generation sequencing. MRD testing has become an important tool for assessing treatment response and recurrence risk in blood cancers such as leukemia, lymphoma, and multiple myeloma, while its application in solid tumors is expanding with the development of circulating tumor DNA-based approaches.
This report delivers an in-depth assessment of the market by analyzing technological innovations, clinical adoption trends, regulatory developments, reimbursement changes, pharmaceutical research activities, and competitive strategies shaping industry growth. It evaluates how advances in sequencing, digital PCR, flow cytometry, liquid biopsy, methylation analysis, and bioinformatics are improving the sensitivity and utility of MRD testing. The study also examines the increasing use of MRD as a clinical trial endpoint and its expanding role in oncology drug development, treatment monitoring, and personalized treatment decisions.
Market Dynamics
The growing incidence of cancer and increasing number of cancer survivors remain among the primary drivers of the MRD testing market. The U.S. recorded an estimated 2.04 million new cancer cases in 2025, while the number of people living with a history of cancer reached 18.6 million and is projected to exceed 22 million by 2035. As more patients achieve remission following treatment, the need for sensitive and repeated monitoring to identify residual disease and assess the risk of relapse is increasing. MRD status is also gaining importance in multiple myeloma, leukemia, and lymphoma due to its association with treatment response and patient outcomes.
The establishment of MRD as a regulatory endpoint is further supporting market growth. In April 2024, the U.S. FDA's Oncologic Drugs Advisory Committee voted unanimously that available data supported the use of MRD as an intermediate clinical endpoint for accelerated approval in multiple myeloma. In January 2026, the FDA issued draft guidance defining MRD negativity assessed in bone marrow using flow cytometry-based or sequencing-based methods as an endpoint that can support accelerated approval. This regulatory acceptance is expanding the role of MRD testing beyond routine clinical monitoring and increasing demand from pharmaceutical and biopharmaceutical companies conducting oncology clinical trials.
Increasing adoption of personalized treatments and targeted therapies in oncology is also creating opportunities for MRD testing. As researchers increasingly identify molecular characteristics of individual tumors, MRD status is being used to evaluate treatment response, guide treatment duration, and support decisions related to therapeutic intensity. The incorporation of MRD-guided treatment duration into clinical guidelines for chronic lymphocytic leukemia further demonstrates the expanding role of MRD assessment throughout the treatment pathway rather than as a single post-treatment measurement.
Despite favorable market conditions, several challenges continue to influence MRD testing adoption. The high sensitivity required for detecting very low levels of residual disease creates technical and analytical challenges, while differences in methodologies, sample handling, reporting standards, and interpretation can affect the comparability of results across laboratories. In addition, access to advanced sequencing, digital PCR, and specialized flow cytometry technologies can be limited in certain healthcare settings. Reimbursement differences across countries and the absence of assay-specific coverage frameworks in several markets can also affect the adoption and utilization of MRD testing.
The market nevertheless presents substantial long-term opportunities. The expanding use of MRD testing in solid tumors is creating a significant area for market development as circulating tumor DNA-based technologies mature. Published evidence supports the prognostic and predictive utility of ctDNA-based MRD across gastrointestinal, lung, breast, and other solid malignancies. Increasing reimbursement coverage for liquid biopsy-based MRD assays, combined with advances in tissue-free detection, whole-genome sequencing, and methylation-based approaches, is expected to broaden the clinical applications of MRD testing.
Segment Analysis
The report provides detailed market analysis across offering, technology, application, sample type, customer type, and geography, enabling stakeholders to identify high-growth business opportunities and evolving trends in MRD testing.
Based on offering, the market is segmented into assays and reagents, instruments, and software and services. Assays and reagents represent an important component of the market due to the recurring consumption associated with serial MRD monitoring, in which testing is performed at multiple timepoints during and after treatment. Software and services are expected to witness strong growth as MRD testing generates increasingly complex datasets requiring advanced analytical, interpretation, reporting, and data management capabilities.
Based on technology, the market is segmented into flow cytometry, polymerase chain reaction, next-generation sequencing, and other technologies. Next-generation sequencing represents a major technology segment as sequencing-based approaches provide high sensitivity and enable the detection of multiple molecular targets within a single analysis. Continued improvements in sequencing platforms, bioinformatics, and assay sensitivity are supporting the expansion of sequencing-based MRD testing. Flow cytometry and PCR-based methods also remain important due to their established clinical use in hematological malignancies.
Based on application, the market is segmented into blood cancers and solid tumors. Blood cancers currently represent a major application area due to the established use of MRD testing in leukemia, lymphoma, and multiple myeloma. Solid tumors are expected to register strong growth as circulating tumor DNA-based approaches mature and clinical evidence, reimbursement coverage, and treatment monitoring applications expand across colorectal, lung, breast, and other cancers.
Based on sample type, the market is segmented into blood, bone marrow, and other sample types. Blood represents an important sample type because it enables repeated and minimally invasive monitoring and is particularly suitable for circulating tumor DNA-based MRD testing in solid tumors. Bone marrow remains essential for MRD assessment in several hematological malignancies and is specifically identified in the FDA's draft guidance for evaluating MRD as a regulatory endpoint in multiple myeloma.
The report further analyzes the market across pharmaceutical and biopharmaceutical companies, hospitals, diagnostic laboratories, and academic and research organizations/institutions. Pharmaceutical and biopharmaceutical companies represent a major customer group as MRD testing becomes increasingly integrated into oncology clinical development and registrational trials. Hospitals and diagnostic laboratories also represent important end users as MRD testing becomes increasingly incorporated into treatment monitoring and clinical decision-making.
Regional Analysis
The report provides comprehensive market analysis across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Regional evaluations consider cancer incidence, oncology treatment infrastructure, reimbursement policies, regulatory frameworks, availability of advanced diagnostic technologies, clinical adoption, pharmaceutical research activity, and laboratory capabilities influencing market growth.
North America is expected to account for a leading share of the global MRD testing market, supported by established reimbursement mechanisms, advanced oncology infrastructure, extensive clinical research activity, and the presence of major MRD testing companies. The Molecular Diagnostic Services Program provides an assay-specific reimbursement framework for MRD testing, while the Medicare Clinical Laboratory Fee Schedule has established a published price for next-generation sequencing-based MRD testing. The region also hosts major laboratory service providers, including Natera and Adaptive Biotechnologies.
Europe also represents an important market, supported by advanced healthcare systems, established cancer treatment infrastructure, genomic medicine capabilities, and increasing emphasis on standardized molecular diagnostics. The region's regulatory environment is influenced by the In Vitro Diagnostic Regulation, while quality-control and standardization initiatives such as the Euro MRD quality control program and EuroFlow Consortium are supporting consistent approaches to molecular and flow cytometry-based disease assessment.
Asia-Pacific is expected to register the fastest growth during the forecast period. Increasing cancer incidence, expanding healthcare infrastructure, growing adoption of precision medicine, and increasing availability of advanced molecular diagnostic technologies are supporting market development across the region. However, the absence of an assay-specific reimbursement framework equivalent to the U.S. Molecular Diagnostic Services Program means that direct patient payment remains an important factor influencing testing adoption in several countries. China's regulatory framework for next-generation sequencing-based reagents for tumor gene variation detection in plasma specimens is also creating a foundation for the development of circulating tumor DNA-based MRD testing.
Latin America and the Middle East & Africa are also expected to present emerging opportunities as cancer diagnostic infrastructure improves, precision oncology programs expand, and healthcare providers increasingly adopt molecular testing technologies. Increasing awareness of personalized treatment and the expansion of oncology diagnostic services are expected to support gradual adoption of MRD testing across these regions.
Competitive Landscape
The report presents a comprehensive evaluation of the competitive environment by examining the strategic positioning of leading market participants, their MRD testing portfolios, assay technologies, sequencing and digital PCR capabilities, clinical evidence, regulatory activities, reimbursement expansion, partnerships, acquisitions, product launches, and recent business developments.
Competitive benchmarking enables stakeholders to evaluate companies based on assay sensitivity, technology capabilities, clinical application coverage, sample types, analytical platforms, regulatory status, reimbursement coverage, testing capacity, and geographic presence. The study also analyzes how market participants are leveraging next-generation sequencing, digital PCR, liquid biopsy, methylation analysis, whole-genome sequencing, and advanced bioinformatics to strengthen their positions in the rapidly evolving MRD testing market.
Key companies profiled in the report include Natera, Inc., Adaptive Biotechnologies Corporation, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Illumina, Inc., Thermo Fisher Scientific, Inc., QIAGEN N.V., Guardant Health, Inc., NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., Exact Sciences Corporation, Integrated DNA Technologies, Inc., Twist Bioscience Corporation, Sysmex Corporation, Invivoscribe, Inc., and other prominent companies operating in the MRD testing market.
How This Report Helps
- Provides accurate market size estimates and long-term forecasts for the global Minimal Residual Disease (MRD) Testing Market.
- Evaluates the impact of cancer incidence, cancer survivorship, precision oncology, regulatory acceptance, and personalized treatment on market growth.
- Identifies high-growth opportunities across offerings, technologies, applications, sample types, customer types, and geographic regions.
- Analyzes emerging technology trends, including next-generation sequencing, digital PCR, liquid biopsy, whole-genome sequencing, methylation-based detection, and advanced bioinformatics.
- Evaluates the impact of regulatory developments and reimbursement expansion on the adoption of MRD testing in clinical and pharmaceutical applications.
- Benchmarks leading companies based on assay portfolios, technology capabilities, clinical evidence, regulatory developments, reimbursement coverage, and competitive positioning.
- Supports product development, investment planning, partnership evaluation, market entry, competitive benchmarking, and business expansion strategies.
- Delivers actionable market intelligence for diagnostic companies, pharmaceutical and biotechnology companies, hospitals, diagnostic laboratories, research institutions, investors, distributors, and other stakeholders.
Key Questions Answered
- What is the current size of the global Minimal Residual Disease (MRD) Testing Market, and how is it expected to evolve through 2036?
- Which technological, clinical, regulatory, and economic factors are driving market growth?
- What are the major drivers, restraints, opportunities, and challenges influencing the development of the MRD testing market?
- Which offering, technology, application, sample type, customer type, and regional segments are expected to experience strong growth during the forecast period?
- How is the increasing incidence of cancer and growing survivor population influencing demand for MRD monitoring?
- How is the regulatory acceptance of MRD as an endpoint for accelerated approval influencing pharmaceutical and biopharmaceutical demand?
- How are advances in next-generation sequencing, digital PCR, flow cytometry, and liquid biopsy transforming MRD testing?
- What opportunities are emerging from the growing use of MRD testing in solid tumors?
- How are reimbursement policies and coverage decisions influencing the adoption of MRD testing across major markets?
- Which geographic markets present significant business opportunities for MRD testing providers?
- Who are the leading companies operating in the MRD testing market, and what strategies are they adopting?
- What recent product launches, partnerships, acquisitions, regulatory developments, reimbursement expansions, and technological innovations are shaping the competitive landscape?
- How can stakeholders leverage market intelligence from this report to support investment decisions, product development, competitive benchmarking, market entry, and long-term business strategy?
TABLE OF CONTENTS
- Table of Contents
1 Introduction
- 1.1 Market Definition
- 1.2 Market Ecosystem
- 1.3 Currency & Limitations
- 1.4 Key Stakeholders
2 Research Methodology
- 2.1 Research Process
- 2.2 Data Collection & Validation Process
- 2.2.1 Secondary Research
- 2.2.2 Primary Research
- 2.3 Market Sizing & Forecasting
- 2.3.1 Market Size Estimation Approach
- 2.3.2 Growth Forecast Approach
- 2.4 Assumptions for the Study
3 Executive Summary
- 3.1 Market Overview
- 3.2 Market Dynamics
- 3.3 Segmental Analysis
- 3.3.1 By Offering
- 3.3.2 By Technology
- 3.3.3 By Application
- 3.3.4 By Sample Type
- 3.3.5 By Customer Type
- 3.3.6 By Geography
- 3.4 Competitive Landscape
4 Market Insights
- 4.1 Overview
- 4.2 Factors Affecting Market Growth
- 4.2.1 Drivers
- 4.2.1.1 Growing Incidence of Cancer
- 4.2.1.2 Establishment of MRD as an Endpoint Supporting Accelerated Approval
- 4.2.1.3 Increasing Investments & Funding for MRD Testing & Research
- 4.2.2 Restraints
- 4.2.2.1 High Costs of Minimal Residual Disease Testing
- 4.2.3 Opportunities
- 4.2.3.1 Rising Adoption of Personalized Treatments & Targeted Therapies in the Field of Oncology
- 4.2.3.2 Growing Use of MRD Testing in Cases of Solid Tumors
- 4.2.4 Challenges
- 4.2.4.1 Chances of False Positive/Negative Results
- 4.2.5 Trends
- 4.2.5.1 Consolidation of Digital PCR
- 4.2.5.2 Whole Genome and Methylation Based MRD Detection
- 4.2.5.3 Integration of Artificial Intelligence into MRD Interpretation
- 4.2.1 Drivers
- 4.3 Regulatory Analysis
- 4.3.1 North America
- 4.3.1.1 U.S.
- 4.3.1.2 Canada
- 4.3.2 Europe
- 4.3.3 Asia Pacific
- 4.3.3.1 China
- 4.3.3.2 Japan
- 4.3.3.3 India
- 4.3.4 Latin America
- 4.3.5 Middle East & Africa
- 4.3.1 North America
- 4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Buyers
- 4.4.2 Bargaining Power of Suppliers
- 4.4.3 Threat of Substitutes
- 4.4.4 Threat of New Entrants
- 4.4.5 Degree of Competition
- 4.5 Technology Evolution Roadmap
5 Market Assessment, By Offering
- 5.1 Overview
- 5.2 Assays & Reagents
- 5.3 Instruments
- 5.4 Software & Services
6 Market Assessment, By Technology
- 6.1 Overview
- 6.2 Flow Cytometry
- 6.3 Polymerase Chain Reaction
- 6.4 Next Generation Sequencing
- 6.5 Other Technologies
7 Market Assessment, By Application
- 7.1 Overview
- 7.2 Blood Cancers
- 7.2.1 Lymphoma
- 7.2.2 Leukemia
- 7.2.2.1 Acute Lymphoblastic Leukemia (ALL)
- 7.2.2.2 Chronic Lymphocytic Leukemia (CLL)
- 7.2.2.3 Other Leukemias
- 7.2.3 Multiple Myeloma
- 7.2.4 Other Blood Cancers
- 7.3 Solid Tumors
8 Market Assessment, By Sample Type
- 8.1 Overview
- 8.2 Blood
- 8.3 Bone Marrow
- 8.4 Other Sample Types
9 Market Assessment, By Customer Type
- 9.1 Overview
- 9.2 Pharmaceutical & Biopharmaceutical Companies
- 9.3 Hospitals
- 9.4 Diagnostic Laboratories
- 9.5 Academic & Research Organizations/Institutions
10 Market Assessment, By Geography
- 10.1 Overview
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 U.K.
- 10.3.3 France
- 10.3.4 Italy
- 10.3.5 Spain
- 10.3.6 Switzerland
- 10.3.7 Netherlands
- 10.3.8 Rest of Europe
- 10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 South Korea
- 10.4.5 Australia
- 10.4.6 Rest of Asia Pacific
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
- 10.6 Middle East & Africa
11 Competitive Landscape
- 11.1 Overview
- 11.2 Key Growth Strategies
- 11.3 Competitive Benchmarking
- 11.4 Competitive Dashboard
- 11.4.1 Industry Leaders
- 11.4.2 Market Differentiators
- 11.4.3 Vanguards
- 11.4.4 Emerging Companies
- 11.5 Market Share Analysis
- 11.5.1 Natera, Inc. (U.S.)
- 11.5.2 F. Hoffmann La Roche Ltd. (Switzerland)
- 11.5.3 Bio Rad Laboratories, Inc. (U.S.)
- 11.5.4 Adaptive Biotechnologies Corporation (U.S.)
12 Company Profiles
- 12.1 Natera, Inc.
- 12.2 Adaptive Biotechnologies Corporation
- 12.3 F. Hoffmann La Roche Ltd.
- 12.4 Bio Rad Laboratories, Inc.
- 12.5 Illumina, Inc.
- 12.6 Thermo Fisher Scientific Inc.
- 12.7 QIAGEN N.V.
- 12.8 Guardant Health, Inc.
- 12.9 NeoGenomics Laboratories, Inc.
- 12.10 Myriad Genetics, Inc.
- 12.11 Exact Sciences Corporation
- 12.12 Integrated DNA Technologies, Inc.
- 12.13 Twist Bioscience Corporation
- 12.14 Sysmex Corporation
- 12.15 Invivoscribe, Inc.
(Each Profile Covers Company Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis)
13 Appendix
- 13.1 Available Customization
- 13.2 Questions Answered in This Report
- 13.3 Related Reports
- 13.4 About Meticulous Research
LIST OF TABLES
List of Tables
- Table 1 Cancer Recurrence Rates, By Cancer Type
- Table 2 FDA Approved Personalized Therapies For Cancer
- Table 3 Regulatory Authorities Governing IVD, Flow Cytometry, PCR, And NGS Products, By Country/Region
- Table 4 Global Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 5 Global Minimal Residual Disease Testing Assays & Reagents Market, By Country/Region, 2024 To 2036 (USD Million)
- Table 6 Global Minimal Residual Disease Testing Instruments Market, By Country/Region, 2024 To 2036 (USD Million)
- Table 7 Global Minimal Residual Disease Testing Software & Services Market, By Country/Region, 2024 To 2036 (USD Million)
- Table 8 Global Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 9 Global Flow Cytometry Based Minimal Residual Disease Testing Market, By Country/Region, 2024 To 2036 (USD Million)
- Table 10 Global PCR Based Minimal Residual Disease Testing Market, By Country/Region, 2024 To 2036 (USD Million)
- Table 11 Global NGS Based Minimal Residual Disease Testing Market, By Country/Region, 2024 To 2036 (USD Million)
- Table 12 Global Minimal Residual Disease Testing Market For Other Technologies, By Country/Region, 2024 To 2036 (USD Million)
- Table 13 Global Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 14 Global Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 15 Global Minimal Residual Disease Testing Market For Blood Cancers, By Country/Region, 2024 To 2036 (USD Million)
- Table 16 Global Minimal Residual Disease Testing Market For Lymphoma, By Country/Region, 2024 To 2036 (USD Million)
- Table 17 Global Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 18 Global Minimal Residual Disease Testing Market For Leukemia, By Country/Region, 2024 To 2036 (USD Million)
- Table 19 Global Minimal Residual Disease Testing Market For Acute Lymphoblastic Leukemia, By Country/Region, 2024 To 2036 (USD Million)
- Table 20 Global Minimal Residual Disease Testing Market For Chronic Lymphocytic Leukemia, By Country/Region, 2024 To 2036 (USD Million)
- Table 21 Global Minimal Residual Disease Testing Market For Other Leukemias, By Country/Region, 2024 To 2036 (USD Million)
- Table 22 Global Minimal Residual Disease Testing Market For Multiple Myeloma, By Country/Region, 2024 To 2036 (USD Million)
- Table 23 Global Minimal Residual Disease Testing Market For Other Blood Cancers, By Country/Region, 2024 To 2036 (USD Million)
- Table 24 Global Minimal Residual Disease Testing Market For Solid Tumors, By Country/Region, 2024 To 2036 (USD Million)
- Table 25 Global Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 26 Global Blood Based Minimal Residual Disease Testing Market, By Country/Region, 2024 To 2036 (USD Million)
- Table 27 Global Bone Marrow Based Minimal Residual Disease Testing Market, By Country/Region, 2024 To 2036 (USD Million)
- Table 28 Global Other Samples Based Minimal Residual Disease Testing Market, By Country/Region, 2024 To 2036 (USD Million)
- Table 29 Global Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 30 Global Minimal Residual Disease Testing Market For Pharmaceutical & Biopharmaceutical Companies, By Country/Region, 2024 To 2036 (USD Million)
- Table 31 Global Minimal Residual Disease Testing Market For Hospitals, By Country/Region, 2024 To 2036 (USD Million)
- Table 32 Global Minimal Residual Disease Testing Market For Diagnostic Laboratories, By Country/Region, 2024 To 2036 (USD Million)
- Table 33 Global Minimal Residual Disease Testing Market For Academic & Research Organizations/Institutions, By Country/Region, 2024 To 2036 (USD Million)
- Table 34 Global Minimal Residual Disease Testing Market, By Geography, 2024 To 2036 (USD Million)
- Table 35 North America: Minimal Residual Disease Testing Market, By Country, 2024 To 2036 (USD Million)
- Table 36 North America: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 37 North America: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 38 North America: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 39 North America: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 40 North America: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 41 North America: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 42 North America: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 43 U.S.: Estimated Number Of New Cancer Cases By Type & State
- Table 44 U.S.: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 45 U.S.: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 46 U.S.: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 47 U.S.: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 48 U.S.: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 49 U.S.: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 50 U.S.: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 51 Canada: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 52 Canada: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 53 Canada: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 54 Canada: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 55 Canada: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 56 Canada: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 57 Canada: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 58 Europe: Minimal Residual Disease Testing Market, By Country, 2024 To 2036 (USD Million)
- Table 59 Europe: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 60 Europe: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 61 Europe: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 62 Europe: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 63 Europe: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 64 Europe: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 65 Europe: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 66 Germany: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 67 Germany: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 68 Germany: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 69 Germany: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 70 Germany: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 71 Germany: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 72 Germany: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 73 U.K.: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 74 U.K.: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 75 U.K.: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 76 U.K.: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 77 U.K.: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 78 U.K.: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 79 U.K.: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 80 France: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 81 France: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 82 France: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 83 France: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 84 France: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 85 France: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 86 France: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 87 Italy: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 88 Italy: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 89 Italy: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 90 Italy: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 91 Italy: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 92 Italy: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 93 Italy: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 94 Spain: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 95 Spain: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 96 Spain: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 97 Spain: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 98 Spain: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 99 Spain: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 100 Spain: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 101 Switzerland: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 102 Switzerland: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 103 Switzerland: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 104 Switzerland: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 105 Switzerland: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 106 Switzerland: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 107 Switzerland: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 108 Netherlands: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 109 Netherlands: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 110 Netherlands: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 111 Netherlands: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 112 Netherlands: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 113 Netherlands: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 114 Netherlands: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 115 Rest Of Europe: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 116 Rest Of Europe: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 117 Rest Of Europe: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 118 Rest Of Europe: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 119 Rest Of Europe: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 120 Rest Of Europe: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 121 Rest Of Europe: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 122 Asia Pacific: Minimal Residual Disease Testing Market, By Country, 2024 To 2036 (USD Million)
- Table 123 Asia Pacific: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 124 Asia Pacific: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 125 Asia Pacific: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 126 Asia Pacific: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 127 Asia Pacific: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 128 Asia Pacific: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 129 Asia Pacific: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 130 China: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 131 China: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 132 China: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 133 China: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 134 China: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 135 China: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 136 China: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 137 Japan: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 138 Japan: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 139 Japan: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 140 Japan: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 141 Japan: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 142 Japan: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 143 Japan: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 144 India: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 145 India: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 146 India: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 147 India: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 148 India: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 149 India: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 150 India: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 151 South Korea: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 152 South Korea: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 153 South Korea: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 154 South Korea: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 155 South Korea: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 156 South Korea: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 157 South Korea: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 158 Australia: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 159 Australia: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 160 Australia: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 161 Australia: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 162 Australia: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 163 Australia: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 164 Australia: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 165 Rest Of Asia Pacific: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 166 Rest Of Asia Pacific: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 167 Rest Of Asia Pacific: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 168 Rest Of Asia Pacific: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 169 Rest Of Asia Pacific: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 170 Rest Of Asia Pacific: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 171 Rest Of Asia Pacific: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 172 Latin America: Minimal Residual Disease Testing Market, By Country, 2024 To 2036 (USD Million)
- Table 173 Latin America: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 174 Latin America: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 175 Latin America: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 176 Latin America: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 177 Latin America: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 178 Latin America: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 179 Latin America: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 180 Brazil: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 181 Brazil: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 182 Brazil: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 183 Brazil: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 184 Brazil: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 185 Brazil: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 186 Brazil: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 187 Mexico: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 188 Mexico: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 189 Mexico: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 190 Mexico: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 191 Mexico: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 192 Mexico: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 193 Mexico: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 194 Rest Of Latin America: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 195 Rest Of Latin America: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 196 Rest Of Latin America: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 197 Rest Of Latin America: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 198 Rest Of Latin America: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 199 Rest Of Latin America: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 200 Rest Of Latin America: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 201 Middle East & Africa: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
- Table 202 Middle East & Africa: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
- Table 203 Middle East & Africa: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
- Table 204 Middle East & Africa: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
- Table 205 Middle East & Africa: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
- Table 206 Middle East & Africa: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
- Table 207 Middle East & Africa: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
- Table 208 Recent Developments, By Company, 2023 To 2026
- Table 209 Competitive Dashboard: Global Minimal Residual Disease Testing Market
- Table 210 Global Minimal Residual Disease Testing Market: Market Share/Ranking Analysis, 2025
- Table 211 Natera, Inc.: Product Portfolio
- Table 212 Natera, Inc.: Recent Developments
- Table 213 Adaptive Biotechnologies Corporation: Product Portfolio
- Table 214 Adaptive Biotechnologies Corporation: Recent Developments
- Table 215 F. Hoffmann La Roche Ltd.: Product Portfolio
- Table 216 F. Hoffmann La Roche Ltd.: Recent Developments
- Table 217 Bio Rad Laboratories, Inc.: Product Portfolio
- Table 218 Bio Rad Laboratories, Inc.: Recent Developments
- Table 219 Illumina, Inc.: Product Portfolio
- Table 220 Illumina, Inc.: Recent Developments
- Table 221 Thermo Fisher Scientific Inc.: Product Portfolio
- Table 222 Thermo Fisher Scientific Inc.: Recent Developments
- Table 223 QIAGEN N.V.: Product Portfolio
- Table 224 QIAGEN N.V.: Recent Developments
- Table 225 Guardant Health, Inc.: Product Portfolio
- Table 226 Guardant Health, Inc.: Recent Developments
- Table 227 NeoGenomics Laboratories, Inc.: Product Portfolio
- Table 228 NeoGenomics Laboratories, Inc.: Recent Developments
- Table 229 Myriad Genetics, Inc.: Product Portfolio
- Table 230 Myriad Genetics, Inc.: Recent Developments
- Table 231 Exact Sciences Corporation: Product Portfolio
- Table 232 Exact Sciences Corporation: Recent Developments
- Table 233 Integrated DNA Technologies, Inc.: Product Portfolio
- Table 234 Integrated DNA Technologies, Inc.: Recent Developments
- Table 235 Twist Bioscience Corporation: Product Portfolio
- Table 236 Twist Bioscience Corporation: Recent Developments
- Table 237 Sysmex Corporation: Product Portfolio
- Table 238 Sysmex Corporation: Recent Developments
- Table 239 Invivoscribe, Inc.: Product Portfolio
- Table 240 Invivoscribe, Inc.: Recent Developments
LIST OF FIGURES
List of Figures
- Figure 1 Market Ecosystem
- Figure 2 Key Stakeholders In The MRD Testing Market
- Figure 3 Research Process
- Figure 4 Key Secondary Sources Referenced For This Study
- Figure 5 Primary Research Techniques
- Figure 6 Breakdown Of Primary Interviews (Supply Side & Demand Side)
- Figure 7 Market Sizing & Growth Forecast Approach
- Figure 8 Global Minimal Residual Disease Testing Market: Key Findings
- Figure 9 Global Minimal Residual Disease Testing Market: Segmental Analysis
- Figure 10 Global MRD Testing Market, By Offering, 2026 Vs. 2036 (USD Million)
- Figure 11 Global MRD Testing Market, By Technology, 2026 Vs. 2036 (USD Million)
- Figure 12 Global MRD Testing Market, By Application, 2026 Vs. 2036 (USD Million)
- Figure 13 Global MRD Testing Market, By Sample Type, 2026 Vs. 2036 (USD Million)
- Figure 14 Global MRD Testing Market, By Customer Type, 2026 Vs. 2036 (USD Million)
- Figure 15 Global MRD Testing Market, By Geography, 2026 Vs. 2036 (USD Million)
- Figure 16 Impact Analysis Of Market Dynamics
- Figure 17 Porter's Five Forces Analysis
- Figure 18 Technology Evolution Roadmap
- Figure 19 Global Minimal Residual Disease Testing Market, By Offering, 2026 Vs. 2036 (USD Million)
- Figure 20 Global Minimal Residual Disease Testing Market, By Technology, 2026 Vs. 2036 (USD Million)
- Figure 21 Global Minimal Residual Disease Testing Market, By Application, 2026 Vs. 2036 (USD Million)
- Figure 22 Global Minimal Residual Disease Testing Market, By Sample Type, 2026 Vs. 2036 (USD Million)
- Figure 23 Global Minimal Residual Disease Testing Market, By Customer Type, 2026 Vs. 2036 (USD Million)
- Figure 24 Global Minimal Residual Disease Testing Market, By Geography, 2026 Vs. 2036 (USD Million)
- Figure 25 North America: Minimal Residual Disease Testing Market Snapshot
- Figure 26 Europe: Minimal Residual Disease Testing Market Snapshot
- Figure 27 Asia Pacific: Minimal Residual Disease Testing Market Snapshot
- Figure 28 Latin America: Minimal Residual Disease Testing Market Snapshot
- Figure 29 Middle East & Africa: Number Of New Cancer Cases, By Country
- Figure 30 Key Growth Strategies Adopted By Leading Players, 2023 To 2026
- Figure 31 Minimal Residual Disease Testing Market: Competitive Benchmarking, By Technology
- Figure 32 Minimal Residual Disease Testing Market: Competitive Benchmarking, By Assay Methodology
- Figure 33 Minimal Residual Disease Testing Market: Competitive Benchmarking, By Region
- Figure 34 Global Minimal Residual Disease Testing Market: Market Share Analysis, 2025
- Figure 35 Natera, Inc.: Financial Snapshot
- Figure 36 Natera, Inc.: SWOT Analysis
- Figure 37 Adaptive Biotechnologies Corporation: Financial Snapshot
- Figure 38 Adaptive Biotechnologies Corporation: SWOT Analysis
- Figure 39 F. Hoffmann La Roche Ltd.: Financial Snapshot
- Figure 40 F. Hoffmann La Roche Ltd.: SWOT Analysis
- Figure 41 Bio Rad Laboratories, Inc.: Financial Snapshot
- Figure 42 Bio Rad Laboratories, Inc.: SWOT Analysis
- Figure 43 Illumina, Inc.: Financial Snapshot
- Figure 44 Illumina, Inc.: SWOT Analysis
- Figure 45 Thermo Fisher Scientific Inc.: Financial Snapshot
- Figure 46 Thermo Fisher Scientific Inc.: SWOT Analysis
- Figure 47 QIAGEN N.V.: Financial Snapshot
- Figure 48 QIAGEN N.V.: SWOT Analysis
- Figure 49 Guardant Health, Inc.: Financial Snapshot
- Figure 50 Guardant Health, Inc.: SWOT Analysis
- Figure 51 NeoGenomics Laboratories, Inc.: Financial Snapshot
- Figure 52 NeoGenomics Laboratories, Inc.: SWOT Analysis
- Figure 53 Myriad Genetics, Inc.: Financial Snapshot
- Figure 54 Myriad Genetics, Inc.: SWOT Analysis
- Figure 55 Exact Sciences Corporation: Financial Snapshot
- Figure 56 Exact Sciences Corporation: SWOT Analysis
- Figure 57 Integrated DNA Technologies, Inc.: Financial Snapshot
- Figure 58 Integrated DNA Technologies, Inc.: SWOT Analysis
- Figure 59 Twist Bioscience Corporation: Financial Snapshot
- Figure 60 Twist Bioscience Corporation: SWOT Analysis
- Figure 61 Sysmex Corporation: Financial Snapshot
- Figure 62 Sysmex Corporation: SWOT Analysis
- Figure 63 Invivoscribe, Inc.: Financial Snapshot
- Figure 64 Invivoscribe, Inc.: SWOT Analysis
